Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
The shaded area represents net assets as a proportion of total assets. It is calculated from the two amounts reported by the company.
Revenue declined in the drug discovery support business because fewer studies were completed, but the loss narrowed as costs were reduced through streamlined business operations. Revenue and profit increased in the investment and consulting business due to a recovery in the e-commerce market, completion of large orders, capture of demand, price pass-through, and inventory and cost management.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥3,659,068 thousand (YoY +14.4%) |
| Operating profit | ¥163,500 thousand (YoY +261.2%) |
| Ordinary income | ¥156,383 thousand (YoY +154.3%) |
| Profit attributable to owners of the parent | ¥136,032 thousand (YoY +404.6%) |
| Total assets | ¥9,728,846 thousand |
| Net assets | ¥4,934,338 thousand |
| Segment revenue | Segment Drug Discovery Support Business / Net Sales ¥435,646 thousand / Year-on-year (%) -22.9, Segment Investment and consulting business / Net Sales ¥3,224,975 thousand / Year-on-year (%) 22.4 |
| Segment profit | Segment Drug Discovery Support Business / Segment profit ¥-14,821 thousand / Year-on-year (%) Not disclosed, Segment Investment and consulting business / Segment profit ¥220,501 thousand / Year-on-year (%) 87.6 |
| Depreciation and amortization | ¥24,495 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥825 thousand / Extraordinary loss Business restructuring loss ¥536 thousand |
| Disclosure regarding the going concern assumption | Not applicable. |
| Factors Behind Changes in Business Performance | Revenue declined in the drug discovery support business because fewer studies were completed, but the loss narrowed as costs were reduced through streamlined business operations. Revenue and profit increased in the investment and consulting business due to a recovery in the e-commerce market, completion of large orders, capture of demand, price pass-through, and inventory and cost management. |
Items this document does not state (22)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the drug discovery support business, revenue declined because fewer studies were completed, while costs fell and the loss narrowed as a result of streamlined business operations. In the investment and consulting business, revenue and profit increased due to a recovery in the e-commerce market, completion of large orders, capture of demand, price pass-through, and inventory and cost management.